Mugen Terzioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mugen Terzioglu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Aysegul Tokatli
Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
2 shared publicationsSerap Emre
Department of Medical Biology, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
2 shared publicationsTurgay Coskun
Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
2 shared publicationsBirgit Weber
Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide S.A.5006, Australia
1 shared publicationImran Ozalp
Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
1 shared publicationJohn J. Hopwood
Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide S.A.5006, Australia
1 shared publication
Latest Publications
- 19 November 2002
- Published by Hindawi Limited in Human Mutation
- Vol. 20 (6) , 477-478
Molecular analysis of Turkish mucopolysaccharidosis IVA (Morquio A) patients: identification of novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder caused by the deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase (GALNS; EC 3.1.6.4). The deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase leads to lysosomal accumulation of undegraded glycosaminoglycans, keratan sulfate and chondroitin‐6‐sulfate. Mutation screening of the GALNS gene was performed by SSCP and direct sequence analyses using genomic DNA samples from 10 Morquio A patients. By nonradioactive SSCP screening, 6 different gene mutations and 2 polymorphisms were identified in 10 severely affected MPS IVA patients. Five of the mutations and one of the polymorphisms are novel. The vast majority of the gene alterations were found to be single nucleotide deletions (389delG, 929delG, and 763delT) or insertions (1232‐1233insT). The other two mutations were one previously identified missense mutation (Q473X) and one novel nonsense (P179S) mutation. Together they account for 95% of the disease alleles of the patients investigated. Beside mutations, one previously identified E477 polymorphism and one novel W520 polymorphism were found among Turkish MPS IVA patients.
- 19 November 2002
- Published by Hindawi Limited in Human Mutation
- Vol. 20 (6) , 477-478
Molecular analysis of Turkish mucopolysaccharidosis IVA (Morquio A) patients: identification of novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder caused by the deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase (GALNS; EC 3.1.6.4). The deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase leads to lysosomal accumulation of undegraded glycosaminoglycans, keratan sulfate and chondroitin‐6‐sulfate. Mutation screening of the GALNS gene was performed by SSCP and direct sequence analyses using genomic DNA samples from 10 Morquio A patients. By nonradioactive SSCP screening, 6 different gene mutations and 2 polymorphisms were identified in 10 severely affected MPS IVA patients. Five of the mutations and one of the polymorphisms are novel. The vast majority of the gene alterations were found to be single nucleotide deletions (389delG, 929delG, and 763delT) or insertions (1232‐1233insT). The other two mutations were one previously identified missense mutation (Q473X) and one novel nonsense (P179S) mutation. Together they account for 95% of the disease alleles of the patients investigated. Beside mutations, one previously identified E477 polymorphism and one novel W520 polymorphism were found among Turkish MPS IVA patients.
- Open Access
- 7 January 2002
- Published by Hindawi Limited in Human Mutation
- Vol. 19 (2) , 184-185
Sanfilippo syndrome in Turkey: Identification of novel mutations in subtypes A and B
Sanfilippo syndrome (mucopolysaccharidosis type III, MPS III) is a progressive disorder in which patients are characterized by severe central nervous system degeneration together with mild somatic disease. MPS III results from a deficiency in one of the four enzymes involved in the degradation of heparan sulfate, with sulfamidase (SGSH) being deficient in MPS IIIA and a‐N‐acetylglucosaminidase (NAGLU) deficient in MPS IIIB. Mutation screening using SSCP/heteroduplex analysis on genomic DNA fragments was performed in five Turkish MPS IIIA and eight Turkish MPS IIIB patients. In this study two mutations of SGSH were identified in MPS IIIA patients: R74C and the novel mutation P288S, and one polymorphism (IVS1+23 C>G). Five different mutations of NAGLU were identified in MPS IIIB patients: L682R, H248R, E153K, g.17703 A>G (novel), and T437I (novel). The clinical data of all patients are reported in detail. A high degree of genetic heterogeneity was observed in the Turkish MPS IIIA and MPS IIIB patients.
- 7 January 2002
- Published by Hindawi Limited in Human Mutation
- Vol. 19 (2) , 184-185
Open AccessSanfilippo syndrome in Turkey: Identification of novel mutations in subtypes A and B
Sanfilippo syndrome (mucopolysaccharidosis type III, MPS III) is a progressive disorder in which patients are characterized by severe central nervous system degeneration together with mild somatic disease. MPS III results from a deficiency in one of the four enzymes involved in the degradation of heparan sulfate, with sulfamidase (SGSH) being deficient in MPS IIIA and a‐N‐acetylglucosaminidase (NAGLU) deficient in MPS IIIB. Mutation screening using SSCP/heteroduplex analysis on genomic DNA fragments was performed in five Turkish MPS IIIA and eight Turkish MPS IIIB patients. In this study two mutations of SGSH were identified in MPS IIIA patients: R74C and the novel mutation P288S, and one polymorphism (IVS1+23 C>G). Five different mutations of NAGLU were identified in MPS IIIB patients: L682R, H248R, E153K, g.17703 A>G (novel), and T437I (novel). The clinical data of all patients are reported in detail. A high degree of genetic heterogeneity was observed in the Turkish MPS IIIA and MPS IIIB patients.